Navigation Links
Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test

AUSTIN, Texas, Nov. 28, 2012 /PRNewswire/ -- Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1® which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer.

Vermillion, Inc. (NASDAQ: VRML), the molecular diagnostics company which developed and currently markets the test, had reported positive top-line results of the study in July. Referred to as "OVA500," the study confirms and extends the findings of the first OVA1 pivotal study published last year in Obstetrics & Gynecology by Dr. Fred Ueland of the University of Kentucky.

The OVA500 results were published online by Gynecologic Oncology on November 22 in the article, "Ovarian Malignancy Risk Stratification of the Adnexal Mass Using a Multivariate Index Assay." The article was authored by Dr. Robert E. Bristow, the director of Gynecologic Oncology Services at UC Irvine Healthcare and former director of gynecologic oncology at Johns Hopkins.

The multi-center study investigated OVA1 performance in the pre-surgical detection of malignancy among 494 women prospectively enrolled from non-gynecologic oncology practices. Sensitivity across all types of ovarian cancers was 96% when OVA1 was added to routine clinical assessment, and this result was nearly identical to the first pivotal study. Importantly, within the test group OVA1 identified 83% of cancers missed by clinical assessment and 71% of cancers missed by CA125.

"The publication of the OVA500 study advances our strategic plan to increase physician adoption and payer coverage, leading to incorporation of OVA1 into the standard of care for ovarian cancer," said Bruce A. Huebner, Vermillion's interim CEO. "The publication of a second independent prospective, multi-center study such as this is considered critically important by many doctors, payers and professional societies. Test data generated from nearly 500 patients enrolled at 27 centers, including 17 new sites, demonstrated the robust performance of OVA1 across diverse geographic settings."

"Both our initial clinical study and OVA500 showed that all combined modalities used in routine clinical assessment failed to predict cancers at a rate of more than 24%. But when adding OVA1, the rate of cancers missed was little more than 4% in each study," continued Huebner. "Now more than ever, we believe the evidence warrants that OVA1 be incorporated into a standardized pre-surgical assessment of adnexal masses."

Dr. Bristow commented: "New tools for the sensitive detection and referral of ovarian cancer are badly needed, given the more than 15,000 women who die every year from this disease in the U.S. The OVA500 study confirmed in a new patient cohort that about 96% of malignancies were detected by adding OVA1 to clinical assessment, and these included 91% of early-stage disease and 94% of premenopausal cancers. At the same time, the majority of subjects with benign disease were classified as low risk, with 98% of negative tests resulting in a benign pathology finding. Thanks to diagnostic advances like OVA1, there is real hope that the majority of women with ovarian cancer will undergo surgery by a qualified gynecologic oncologist, which is one of the most powerful determinants of survival."

The OVA500 study abstract and publication is available here.OVA500 Study Summary:Results (N=494) 1Clinical
Impression (CI)CA125-IIOVA1OVA1 & CISensitivity %73.9



95.7Specificity %92.5



50.7PPV %69.4



30.8NPV %93.9



98.1% Cancers Missed26.1



4.3First OVA1 Study Summary:Results (N=516) 2Clinical
Impression (CI)CA125-IIOVA1OVA1 & CISensitivity %75.1



95.6Specificity %79.1



34.6PPV %62.0



39.8NPV %87.5



94.6% Cancers Missed24.9



1. Bristow, et al., Gynecologic Oncology, November 2012

2. Ueland FR, DeSimone CP, Seamon LG, et al. ObstetGynecol. 2011;117(6):1289-1297.

About Gynecologic Oncology
Gynecologic Oncology is the official publication of Society for Gynecologic Oncology, and has been recognized as having the highest impact factor rating of all journals worldwide that publish research on gynecological cancer.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at

Forward-Looking Statements 
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty of finding a suitable successor chief executive officer; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in the company's most recent reports on Form 10-K and Form 10-Q. Copies are available through EDGAR at

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Saddleback Memorial Named First Robotic Training Epicenter for Gynecologic Surgery in Orange County
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
5. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
6. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
7. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
8. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
9. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
11. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Henry ... largest provider of health care products and services to ... its customers that the Henry Schein Disaster Relief Hotline ... operational, logistical or financial issues as a result of ... . The toll-free number for all Henry Schein ...
(Date:10/9/2015)... 9, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... third quarter 2015 financial results on Monday, November 9, ... markets. The Company will host a conference call and ... Eastern Time on November 9, 2015.  ... The financial results and live webcast will be ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) today announced ... jobs to its research and development presence at the Alexandria ... . --> --> ... translational immuno-oncology hub and a Lilly "portal," which will provide ... drug discovery capabilities, including chemistry and lead optimization expertise. ...
Breaking Medicine Technology:
... Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific ... measure and improve quality in the cath lab for ... of using evidence to guide new ways to advance ... quality program with its signature "Quality Improvement Toolkit" to ...
... Bank Pharmaceuticals today announced it has been awarded an ... Institute of Allergy and Infectious Diseases for the development ... treatment of Hepatitis B virus infection.   Under ... $3.9 million over five years in support of its development ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... "My spouse ... our canes falling when leaned against something," said an inventor from Buffalo, N.Y. "This ... cane users face daily." , The CANE REST enables a user to keep a ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical ... specifications for TRACTUS, the world’s first sterile field scanner. , The ... to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require ...
(Date:10/9/2015)... , ... October 09, 2015 , ... "As a nurse, ... inventors from Philadelphia, Pa. "They have to wear large diapers or pads. We came ... They developed the TROUSAFE to absorb urine leaking from the tip of the penis. ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... University researcher will receive a $2.3 million New Innovator ... of synthetic platelets and the technology that makes them ... uses nanotechnology to build platelets of biodegradable polymers, which ... She and fellow researchers initially pursued the technology ...
... (Boston) - Boston Medical Center (BMC) has been awarded ... Heart, Lung and Blood Institute (NHLBI) for investigators from ... Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities. ... understand the effects of Massachusetts health reform on cardiovascular ...
... Reporter , WEDNESDAY, Sept. 29 (HealthDay News) -- Another study ... screening can lower the risk of dying from breast cancer ... Sweden, found that women who were screened cut their risk ... over a 10-year period would save one life, study author ...
... by principal investigator Kang Zhang, MD, PhD, professor of ... Eye Center and director of UCSD,s Institute of Genomic ... NIH Transformative Award. Zhang and co-principal investigators Sheng ... Reh, PhD from the University of Washington, received the ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
... - Patients with triple negative breast cancer that also have ... risk of recurrence, compared to those with the same disease ... University of Texas MD Anderson Cancer Center. The findings ... this select group of triple negative breast cancer patients, as ...
Cached Medicine News:
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
... five different models. Choose mechanical or gravity ... liters), 2.5 cu. Ft. (71.5 liters), or ... Precision Economy Incubators combine a wide temperature ... uniformity. As a result, you will find ...
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Medicine Products: